There are currently 480 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, University of Tennessee Health Science Center and Baptist Memorial Hospital and Cancer Center-Memphis. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
Female
Ages:
35 years and above
Trial Updated:
06/13/2024
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Breast Cancer
Register for Updates
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448
Recruiting
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: Office of Ramesh C. Gupta MD / Shelby Research LLC - Tennessee, Memphis, Tennessee
Conditions: Systemic Lupus Erythematosus
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2024
Locations: Vistagen Clinical Site, Memphis, Tennessee
Conditions: Social Anxiety Disorder
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718
Recruiting
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Gender:
All
Ages:
17 years and below
Trial Updated:
06/12/2024
Locations: St. Jude Children'S Research Hospital, Memphis, Tennessee
Conditions: ALK Fusion-positive Solid or CNS Tumors
Register for Updates
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476
Recruiting
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Gender:
All
Ages:
Between 4 years and 7 years
Trial Updated:
06/12/2024
Locations: DBV Investigative Site, Memphis, Tennessee
Conditions: Allergy, Peanut
Register for Updates
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
NCT05175105
Recruiting
Study ACTIVATE-Kids (AG348-C-023) will evaluate the efficacy and safety of orally administered mitapivat as compared with placebo in pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to < 6 years, 6 to < 12 years, 12 to < 18 years). Participants will be dosed by age and weight during a double-blind period co... Read More
Gender:
All
Ages:
Between 1 year and 17 years
Trial Updated:
06/12/2024
Locations: St Jude's Children's Research Hospital, Memphis, Tennessee
Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Register for Updates
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738
Recruiting
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed co... Read More
Gender:
All
Ages:
All
Trial Updated:
06/12/2024
Locations: St Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Pyruvate Kinase Deficiency
Register for Updates
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
NCT03598244
Recruiting
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
Between 6 years and 21 years
Trial Updated:
06/12/2024
Locations: Saint Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Primary Central Nervous System Neoplasm
Register for Updates
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03598257
Recruiting
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Breast Inflammatory Carcinoma
Register for Updates
THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing
NCT05437055
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/12/2024
Locations: Methodist U., Memphis, Tennessee
Conditions: Acute Ischemic Stroke, Large Vessel Occlusion
Register for Updates
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Recruiting
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
06/12/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Register for Updates
Transforaminal Lumbar Interbody Fusion (TLIF)
NCT04073563
Recruiting
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 1017 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in A Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indicatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Semmes Murphey, Memphis, Tennessee
Conditions: Degenerative Disease of the Lumbosacral Spine
Register for Updates